Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Tom D who wrote (322)	12/4/1997 3:24:00 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 887

Tom, Nice to see you doing such an excellent job of handling the newfound interest in DEPO. I've been traveling a bunch recently so haven't been able to contribute much. While we're waiting on DepoCyt approval, do you have any idea of the likely timeline for announcements on other drugs in the pipeline? As far as the take the money and run strategy goes, it is a tough call. While no doubt many will move on to other short term trading plays, there is a good likelihood that funds will enter to establish new positions once the company is more securely established with DepoCyt approval. It doesn't take very many new buyers to produce major buying volume, particularly given the relatively light volume DEPO has exhibited. On balance, I would think the upside contribution of new fund buying would be significantly greater than selling by comparatively small players. The visibility of earnings puts the company into a special category among small bio companies. They suddenly become small pharmaceutical companies. DEPO's big advantage is having a technology that can be applied to many uses and should have a significantly higher than average likelihood of getting FDA approval. Increased visibility for their technology following DepoCyt approval will likely stimulate new partnerships. All in all, I think the fun is just beginning. Baird